LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 10 of total 95

Search options

  1. Book: Eosinophils

    Walsh, Garry M.

    methods and protocols

    (Methods in molecular biology ; 2241 ; Springer protocols)

    2021  

    Author's details edited by Garry M. Walsh
    Series title Methods in molecular biology ; 2241
    Springer protocols
    Collection
    Keywords Eosinophils
    Subject code 612.112
    Language English
    Size XII, 297 Seiten, Illustrationen
    Edition Second edition
    Publisher Humana Press
    Publishing place New York, NY
    Publishing country United States
    Document type Book
    HBZ-ID HT020803886
    ISBN 978-1-0716-1094-7 ; 9781071610954 ; 1-0716-1094-5 ; 1071610953
    Database Catalogue ZB MED Medicine, Health

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Shelf markLoan statusLocation
    Zs A 7042 -2241- verfügbar in Königswinter Königswinter

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  2. Book: Eosinophils

    Walsh, Garry M.

    methods and protocols

    (Methods in molecular biology ; 1178 ; Springer protocols)

    2014  

    Author's details ed. by Garry M. Walsh
    Series title Methods in molecular biology ; 1178
    Springer protocols
    Collection
    Keywords Eosinophils
    Subject code 612.112
    Language English
    Size XII, 324 S. : Ill., graph. Darst., 27 cm
    Publisher Humana Press
    Publishing place New York u.a.
    Publishing country United States
    Document type Book
    Note Formerly CIP. ; Includes bibliographical references and index
    HBZ-ID HT018358887
    ISBN 978-1-4939-1015-1 ; 9781493910168 ; 1-4939-1015-9 ; 1493910167
    Database Catalogue ZB MED Medicine, Health

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Shelf markLoan statusLocation
    Zs A 7042 -1178- verfügbar in Königswinter Königswinter

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  3. Article ; Online: Recent developments in the use of monoclonal antibodies targeting the type 2 cytokines for severe asthma treatment.

    Walsh, Garry M

    Advances in pharmacology (San Diego, Calif.)

    2023  Volume 98, Page(s) 31–54

    Abstract: Severe or refractory asthma is seen in approximately 5% of asthmatic subjects who have unsatisfactory symptom control despite adherence to high-dose inhaled glucocorticoid therapies resulting in significant morbidity, reduced quality of life with ... ...

    Abstract Severe or refractory asthma is seen in approximately 5% of asthmatic subjects who have unsatisfactory symptom control despite adherence to high-dose inhaled glucocorticoid therapies resulting in significant morbidity, reduced quality of life with attendant implications for healthcare costs. Marked heterogeneity in symptoms and at the molecular phenotypic level are hallmarks of asthma resulting in the requirement of specifically targeted treatments to block the key pathways of the disease. Monoclonal antibody (mAb)-based biologics targeted at inhibition of the type 2 cytokines IL-4, IL-5 and IL-13 have become established as effective treatments for severe asthma, with significant clinical benefit seen in carefully selected patient populations that take asthma phenotypes and endotypes into account. The further development of reproducible and straightforward discriminatory biomarkers may aid identification of those patients most likely to benefit from treatment with these interventions.
    MeSH term(s) Humans ; Antibodies, Monoclonal/pharmacology ; Antibodies, Monoclonal/therapeutic use ; Cytokines/therapeutic use ; Anti-Asthmatic Agents/adverse effects ; Quality of Life ; Interleukin-5/metabolism ; Interleukin-5/therapeutic use ; Asthma/drug therapy
    Chemical Substances Antibodies, Monoclonal ; Cytokines ; Anti-Asthmatic Agents ; Interleukin-5
    Language English
    Publishing date 2023-04-27
    Publishing country United States
    Document type Journal Article
    ISSN 1557-8925
    ISSN (online) 1557-8925
    DOI 10.1016/bs.apha.2023.04.003
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

    Inter-library loan at ZB MED

    Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

  4. Article ; Online: Anti-IL-5 monoclonal antibodies for the treatment of asthma: an update.

    Walsh, Garry M

    Expert opinion on biological therapy

    2020  Volume 20, Issue 10, Page(s) 1237–1244

    Abstract: Introduction: Asthma exhibits marked heterogeneity in symptoms with severe or refractory asthma representing a clear area of unmet medical need. These patients require more specifically targeted treatments with monoclonal antibody-based biologics ... ...

    Abstract Introduction: Asthma exhibits marked heterogeneity in symptoms with severe or refractory asthma representing a clear area of unmet medical need. These patients require more specifically targeted treatments with monoclonal antibody-based biologics targeted at inhibition of the type 2 cytokines IL-4, IL-5 and IL-13 having considerable potential as effective treatments for severe asthma. For the most part, anti-cytokine-based biologic therapies are more likely to give significant clinical benefit in carefully selected patient populations that take asthma phenotypes and endotypes into account.
    Areas covered: This review is based on recent English-language original articles in Pub Med or MedLine that reported significant clinical findings on the current status, therapeutic potential and safety of the anti-IL-5 biologics mepolizumab, reslizumab and benralizumab in the treatment of severe refractory asthma.
    Expert opinion: Anti-IL-5 treatment appears effective in patients with eosinophilic asthma through exacerbation prevention with accumulating evidence of glucocorticoid-sparing effects with an acceptable safety profile for these biologics.
    MeSH term(s) Anti-Asthmatic Agents/therapeutic use ; Antibodies, Monoclonal/therapeutic use ; Antibodies, Monoclonal, Humanized/therapeutic use ; Asthma/drug therapy ; Asthma/epidemiology ; Asthma/immunology ; Asthma/pathology ; Glucocorticoids/therapeutic use ; Humans ; Immunotherapy/methods ; Immunotherapy/trends ; Interleukin-5/immunology ; Treatment Outcome
    Chemical Substances Anti-Asthmatic Agents ; Antibodies, Monoclonal ; Antibodies, Monoclonal, Humanized ; Glucocorticoids ; IL5 protein, human ; Interleukin-5 ; reslizumab (35A26E427H) ; mepolizumab (90Z2UF0E52)
    Language English
    Publishing date 2020-06-25
    Publishing country England
    Document type Journal Article ; Review
    ZDB-ID 2052501-1
    ISSN 1744-7682 ; 1471-2598
    ISSN (online) 1744-7682
    ISSN 1471-2598
    DOI 10.1080/14712598.2020.1782381
    Database MEDical Literature Analysis and Retrieval System OnLINE

    Full text online

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 6094: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  5. Book: The therapeutic index of antihistamines

    Walsh, Garry M.

    (Allergy : Supplement ; 60)

    2000  

    Author's details guest ed.: G. M. Walsh
    Series title Allergy : Supplement ; 60
    Allergy
    Allergy ; Supplement
    Collection Allergy
    Allergy ; Supplement
    Keywords Antihistaminikum ; Therapie ; Pharmakotherapie
    Subject Arzneimitteltherapie ; Arzneitherapie ; Medikamentöse Therapie ; Histaminantagonist ; Medizinische Behandlung ; Behandlung ; Krankenbehandlung
    Language English
    Size 61 S. : Ill., graph. Darst.
    Publisher Munksgaard
    Publishing place Copenhagen
    Publishing country Denmark
    Document type Book
    HBZ-ID HT012738974
    ISBN 87-16-16400-8 ; 978-87-16-16400-1
    Database Catalogue ZB MED Medicine, Health

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Shelf markLoan statusLocation
    Uh III Zs 150 -Suppl.60- verfügbar in Königswinter Königswinter

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  6. Article ; Online: Dupilumab utility in difficult-to-treat asthma.

    M Walsh, Garry

    Immunotherapy

    2019  Volume 11, Issue 4, Page(s) 261–264

    MeSH term(s) Antibodies, Monoclonal, Humanized/therapeutic use ; Asthma/immunology ; Asthma/therapy ; Dermatitis, Atopic/immunology ; Dermatitis, Atopic/therapy ; Eosinophils/immunology ; Humans ; Immunotherapy/methods ; Interleukin-13/metabolism ; Interleukin-4/metabolism ; Receptors, Interleukin-4/immunology ; Signal Transduction
    Chemical Substances Antibodies, Monoclonal, Humanized ; Interleukin-13 ; Receptors, Interleukin-4 ; Interleukin-4 (207137-56-2) ; dupilumab (420K487FSG)
    Language English
    Publishing date 2019-01-23
    Publishing country England
    Document type Editorial
    ISSN 1750-7448
    ISSN (online) 1750-7448
    DOI 10.2217/imt-2018-0184
    Database MEDical Literature Analysis and Retrieval System OnLINE

    Full text online

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

    Inter-library loan at ZB MED

    Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

  7. Article ; Online: Reslizumab in the treatment of severe eosinophilic asthma: an update.

    Walsh, Garry M

    Immunotherapy

    2018  Volume 10, Issue 8, Page(s) 695–698

    Abstract: A marked heterogeneity is exhibited by asthma both clinically and at the molecular level with different phenotypes driven by diverse mechanistic pathways that require specifically targeted treatments. Biologics aimed at IL-4/13, IL-5 or IgE are proven or ...

    Abstract A marked heterogeneity is exhibited by asthma both clinically and at the molecular level with different phenotypes driven by diverse mechanistic pathways that require specifically targeted treatments. Biologics aimed at IL-4/13, IL-5 or IgE are proven or potentially effective treatments for patients with difficult to treat eosinophilic asthma. Importantly, it is now widely accepted that biologic-based therapies give significant clinical improvements in those patient populations where asthma phenotypes are taken into account. Such asthma phenotypes have been identified by reproducible and straightforward discriminatory biomarkers. This short review discusses recent studies of the effectiveness of the anti-IL-5 reslizumab in relation to the use of simple reproducible biomarkers in eosinophilic asthma.
    MeSH term(s) Anti-Asthmatic Agents/therapeutic use ; Antibodies, Monoclonal, Humanized/therapeutic use ; Asthma/drug therapy ; Asthma/immunology ; Biomarkers/metabolism ; Humans ; Interleukin-5/antagonists & inhibitors ; Interleukin-5/metabolism ; Phenotype ; Pulmonary Eosinophilia/drug therapy ; Pulmonary Eosinophilia/immunology ; Safety ; Treatment Outcome
    Chemical Substances Anti-Asthmatic Agents ; Antibodies, Monoclonal, Humanized ; Biomarkers ; IL5 protein, human ; Interleukin-5 ; reslizumab (35A26E427H)
    Language English
    Publishing date 2018-03-20
    Publishing country England
    Document type Journal Article ; Review
    ISSN 1750-7448
    ISSN (online) 1750-7448
    DOI 10.2217/imt-2017-0176
    Database MEDical Literature Analysis and Retrieval System OnLINE

    Full text online

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

    Inter-library loan at ZB MED

    Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

  8. Article ; Online: Recent developments in the use of biologics targeting IL-5, IL-4, or IL-13 in severe refractory asthma.

    Walsh, Garry M

    Expert review of respiratory medicine

    2018  Volume 12, Issue 11, Page(s) 957–963

    Abstract: Introduction: Severe or refractory asthma is seen in approximately 5% of asthmatic subjects who have unsatisfactory symptom control despite adherence to high-dose inhaled glucocorticoid therapies resulting in significant morbidity, reduced quality of ... ...

    Abstract Introduction: Severe or refractory asthma is seen in approximately 5% of asthmatic subjects who have unsatisfactory symptom control despite adherence to high-dose inhaled glucocorticoid therapies resulting in significant morbidity, reduced quality of life and health-care cost implications. Asthma exhibits marked heterogeneity both clinically and at the molecular phenotypic level requiring specifically targeted treatments to block the key pathways of the disease. Monoclonal antibody-based biologics targeted at inhibition of the type 2 cytokines IL-4, IL-5, and IL-13 have considerable potential as effective treatments for severe asthma. Areas covered: This review is based on recent English-language original articles in PubMed or Medline that reported significant clinical findings on the current status, therapeutic potential, and safety of biologics targeted at IL-4, IL-5, and IL-13 in the treatment of asthma together with the potential utility of simple reproducible non-invasive biomarkers to guide the effective use of biologic-based therapy that do not require direct sampling of the airways Expert commentary: The further development of reproducible and straightforward discriminatory non-invasive biomarkers may aid identification of those patients most likely to benefit from treatment with these interventions.
    MeSH term(s) Anti-Asthmatic Agents/therapeutic use ; Antibodies, Monoclonal/therapeutic use ; Antibodies, Monoclonal, Humanized/therapeutic use ; Asthma/drug therapy ; Asthma/immunology ; Humans ; Interleukin-13/antagonists & inhibitors ; Interleukin-4/antagonists & inhibitors ; Interleukin-5/antagonists & inhibitors
    Chemical Substances Anti-Asthmatic Agents ; Antibodies, Monoclonal ; Antibodies, Monoclonal, Humanized ; Interleukin-13 ; Interleukin-5 ; Interleukin-4 (207137-56-2) ; reslizumab (35A26E427H) ; dupilumab (420K487FSG) ; benralizumab (71492GE1FX) ; mepolizumab (90Z2UF0E52)
    Language English
    Publishing date 2018-09-17
    Publishing country England
    Document type Journal Article ; Review
    ZDB-ID 2479146-5
    ISSN 1747-6356 ; 1747-6348
    ISSN (online) 1747-6356
    ISSN 1747-6348
    DOI 10.1080/17476348.2018.1520095
    Database MEDical Literature Analysis and Retrieval System OnLINE

    Full text online

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 6963: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  9. Article ; Online: Severe eosinophilic asthma and mepolizumab.

    Walsh, Garry M

    The Lancet. Respiratory medicine

    2016  Volume 4, Issue 7, Page(s) 528–529

    Language English
    Publishing date 2016-07
    Publishing country England
    Document type Journal Article
    ZDB-ID 2686754-0
    ISSN 2213-2619 ; 2213-2600
    ISSN (online) 2213-2619
    ISSN 2213-2600
    DOI 10.1016/S2213-2600(16)30103-5
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 7041: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  10. Article ; Online: Biologics targeting IL-5, IL-4 or IL-13 for the treatment of asthma - an update.

    Walsh, Garry M

    Expert review of clinical immunology

    2017  Volume 13, Issue 2, Page(s) 143–149

    Abstract: Introduction: The development of monoclonal antibody-based biologics targeted at inhibition of the Th2 cytokines IL-4, IL-5 and IL-13 represent potentially effective treatments for patients with the glucocorticoid refractory eosinophilic asthma ... ...

    Abstract Introduction: The development of monoclonal antibody-based biologics targeted at inhibition of the Th2 cytokines IL-4, IL-5 and IL-13 represent potentially effective treatments for patients with the glucocorticoid refractory eosinophilic asthma phenotype. Areas covered: Asthma exhibits marked heterogeneity both clinically and at the molecular phenotypic level, requiring specifically targeted treatments to block the key pathways of the disease. It is becoming apparent that significant clinical effects with anti-cytokine-based biologic therapies are more likely in carefully selected patient populations that take asthma phenotypes into account. The development of reproducible and straightforward discriminatory biomarkers may aid identification of those patients most likely to benefit from treatment with these expensive interventions. This narrative review is based on English-language original articles in PubMed or Med-Line that reported significant clinical findings published in the last two years on the evidence demonstrating the effectiveness or otherwise of the targeting of IL-4, IL-5, or IL-13 in carefully selected patients with severe refractory asthma. Expert commentary: The use of a baseline peripheral blood eosinophilia as a simple reproducible biomarker to identify patients with particular sub-phenotypes of asthma to guide the effective use of biologic therapy represents a significant step forward.
    MeSH term(s) Animals ; Antibodies, Monoclonal/therapeutic use ; Asthma/immunology ; Asthma/therapy ; Biological Products/therapeutic use ; Drug Resistance ; Eosinophils/immunology ; Expert Testimony ; Glucocorticoids/therapeutic use ; Humans ; Immunotherapy/methods ; Immunotherapy/trends ; Interleukin-13/immunology ; Interleukin-4/immunology ; Interleukin-5/immunology ; Recurrence ; Treatment Outcome
    Chemical Substances Antibodies, Monoclonal ; Biological Products ; Glucocorticoids ; Interleukin-13 ; Interleukin-5 ; Interleukin-4 (207137-56-2)
    Language English
    Publishing date 2017-02
    Publishing country England
    Document type Journal Article ; Review
    ZDB-ID 2274260-8
    ISSN 1744-8409 ; 1744-666X
    ISSN (online) 1744-8409
    ISSN 1744-666X
    DOI 10.1080/1744666X.2016.1216316
    Database MEDical Literature Analysis and Retrieval System OnLINE

    Full text online

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 6661: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

To top